52 results
8-K
EX-99.1
NKGN
NKGen Biotech Inc
11 Apr 24
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
8:05am
focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced … on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics. NKGen is headquartered in Santa
8-K
EX-99.1
NKGN
NKGen Biotech Inc
28 Dec 23
Other Events
4:14pm
of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced the dosing of the first patient in its Phase 1/2a trial … biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK NK cell therapies. NKGen
8-K
EX-99.1
l01mq 6r0
27 Dec 23
NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease
4:02pm
8-K
EX-99.1
am9dk
14 Nov 23
NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
4:36pm
8-K
EX-99.1
mx3clpd
5 Oct 23
Index to Financial Statements
5:12pm
8-K
EX-99.4
50ipir1 tj1x6g
5 Oct 23
Index to Financial Statements
5:12pm
8-K
EX-99.2
tkxdi5l8a
5 Oct 23
Index to Financial Statements
5:12pm
425
EX-99.1
nqlhihvbl
22 Sep 23
Business combination disclosure
9:27am
8-K
EX-99.1
nwvsqqv 2ul24
22 Sep 23
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting
9:26am
424B3
zhdj xf2hvnpp
21 Sep 23
Prospectus supplement
7:31pm
425
EX-99.1
zlqnuc0vh x5wg
14 Sep 23
Business combination disclosure
9:31am
8-K
EX-99.1
74geyr5t6ajn5s
14 Sep 23
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting
9:30am
425
EX-99.1
i58vy0vw5jp
11 Sep 23
Business combination disclosure
11:30am